乌鸦传媒

The has eased a bit, but the vast majority of cancer centers are still "living paycheck to paycheck." (STAT)

Final results from a large clinical trial showed that a achieved cancer signal origin accuracy of 97% in patients with no symptoms of cancer, GRAIL announced.

Janssen announced that the combination of amivantamab (Rybrevant) and lazertinib significantly improved (PFS) in advanced EGFR-mutated non-small cell lung cancer as compared with osimertinib (Tagrisso).

NCI researchers reported encouraging preclinical results with a potential for blood cancers.

A phase III trial of venetoclax (Venclexta) plus dexamethasone in previously treated multiple myeloma, according to a statement from AbbVie.

A pivotal trial of the revumenib for acute myeloid leukemia ended early after data showed the trial met prespecified criteria for hematologic response in certain patients with relapsed/refractory disease, Syndax announced.

Nexcella announced a in an early-phase trial of relapsed/refractory multiple myeloma treated with the investigational B-cell membrane antigen-targeted CAR T-cell therapy NXC-201.

A phase III trial of pembrolizumab (Keytruda) showed significant improvement in among patients with localized muscle-invasive urothelial cancer or locally advanced urothelial cancer.

A study by Susan G. Komen showed that many low-income women with breast cancer struggle to afford , including housing, transportation, and utilities.

Women should pay attention to unusual symptoms that might indicate , an especially aggressive form of the disease. (Ohio State University Comprehensive Cancer Center)

A computer game showed promise for relieving in breast cancer survivors. (University of Texas MD Anderson Cancer Center, Cancer)

Comment